Immunotherapy Boosts Prostate Cancer Treatment, Study Finds
An international research team has demonstrated promising results in the treatment of early-stage prostate cancer by combining immunotherapy with preoperative hormone therapy. The approach aims to enhance the body’s immune response and reduce the presence of cells that hinder its ability to fight the tumor.
How the Combination Therapy Works
The study focused on adding the experimental antibody BMS-986218 to standard preoperative hormone therapy. Researchers found that BMS-986218 helped decrease regulatory T cells within tumors compared to hormone therapy alone. Regulatory T cells can suppress the immune system, preventing it from effectively attacking cancer cells. By reducing these cells, the immunotherapy allows the immune system to mount a stronger defense against the tumor.
Study Details and Findings
The research involved 24 men diagnosed with high-risk localized prostate cancer. Preoperative treatment allowed researchers to analyze the resected tumors and assess the treatment’s impact on immune cells, helping to identify patients most likely to benefit from this approach. ClinicalTrials.gov provides details on the study protocol.
BMS-986218: A Novel Immunotherapy Agent
BMS-986218 is a non-fucosylated human IgG1 anti-CTLA-4 monoclonal antibody designed to optimize CD16 FcγR binding. This enhancement aims to improve T-cell priming and lessen the suppression caused by T-regulatory cells within the tumor microenvironment. Research published in the Journal for ImmunoTherapy of Cancer details the preclinical function demonstrating increased antigen-specific CD8+ effector T cells with BMS-986218 compared to ipilimumab.
Degarelix Acetate and Immunotherapy Combination
The study utilized degarelix acetate, a hormone therapy drug, in combination with BMS-986218. The National Cancer Institute highlights ongoing research evaluating the safety and efficacy of this combination prior to surgery in patients with high-risk prostate cancer.
Safety and Feasibility
Initial findings suggest the treatment is well-tolerated and feasible in the neoadjuvant setting – meaning it’s given before the primary treatment, in this case, radical prostatectomy. A study published in PMC confirms the safety and feasibility of this approach.
Future Directions
This research represents a significant step forward in personalized prostate cancer treatment. By understanding how the immune system responds to this combination therapy, clinicians can potentially identify which patients will benefit most, leading to more effective and targeted treatments. Further research is ongoing to refine the approach and explore its potential in other cancer types.